(STIM) Neuronetics, Inc. Business Model Canvas Research

Neuronetics, Inc. depends on specialized component suppliers for electronics, magnetic coil parts, and other device inputs, because stable supply supports consistent manufacturing and product quality. For a commercialized medical device platform, continuity matters: even one weak supplier link can disrupt output, service levels, and revenue flow.

• Electronics and coil sourcing
• Consistent device quality
• Supply continuity is critical

Service and technology vendors keep Neuronetics' software, IT systems, and field service operations running, so installation, training, and post-sale support stay consistent. In FY2025, this partner layer matters for scaling the Company's U.S. footprint and international support without building every function in-house.

• Supports software and IT uptime
• Backs installation and training
• Helps post-sale service scale
• Extends U.S. and global reach

Neuronetics, Inc. sells NeuroStar to psychiatrists through dedicated sales and field support teams, and this work drives account wins, onboarding, and clinic retention. The same teams help practices adopt the therapy and expand use after launch.

Field coverage matters because the model depends on repeat clinic usage, not one-time sales, so support can directly affect revenue quality and installed-base growth.

• Acquires new psychiatry accounts
• Trains and onboards clinics
• Supports retention and expansion

Neuronetics, Inc. trains physicians and clinic staff on NeuroStar TMS use, then backs that education with clinical evidence that supports adoption and payer coverage. In its latest reported year, this evidence-led model helped drive a 2025 net revenue base of $61.3 million, reinforcing market trust in TMS therapy.

• Train physicians and staff
• Publish clinical evidence
• Support payer confidence
• Improve TMS adoption

Neuronetics, Inc.’s clinical evidence base is a core intangible asset: peer-reviewed data on transcranial magnetic stimulation helps physicians trust outcomes and use the therapy in practice. It also supports payer talks and wider adoption, which matters in a market where reimbursement often decides volume.

• Builds physician confidence
• Supports payer coverage talks
• Drives market adoption

Neuronetics, Inc. runs its headquarters and core operating base from Malvern, Pennsylvania, where corporate, operational, and support teams coordinate U.S. and international commercialization. This central infrastructure keeps product rollout, sales support, and market execution aligned across regions.

• Malvern, Pennsylvania headquarters
• Central corporate and support hub
• Backs U.S. and international sales

Clinic-based physician delivery fits outpatient psychiatry because Neuronetics, Inc.'s treatment is done in a provider office, not an operating room, so care stays noninvasive and easy to schedule. It also lets physicians supervise each session directly, which matters in a market where major depression affects about 21 million U.S. adults each year.

• Office-based, not surgical

• Matches outpatient workflows

• Physician-supervised care

Neuronetics already has a market-tested platform: NeuroStar is a commercial product used in clinics, not a prototype. In 2025, the Company continued scaling through U.S. sales and international distribution, which supports repeatable rollout across sites instead of a one-off device sale.

• Commercial product already in use
• Supports international distribution
• Scales beyond single-clinic adoption

Neuronetics, Inc. supports reimbursement discussions because clinics often need help proving payer coverage for Transcranial Magnetic Stimulation (TMS). This hands-on access support helps reduce denials and delays, which matters for a therapy used in more than 1.6 million treatments since launch and can lift patient access when coverage rules are unclear.

• Helps clinics navigate payer rules
• Supports access and reimbursement talks
• Reduces treatment delays for patients

Neuronetics, Inc. keeps customers engaged after installation because TMS systems need service, maintenance, and replacement parts over time. That turns one sale into recurring contact, which fits a device model where uptime and clinical support matter more than a one-time handoff.

• Service support extends the customer lifecycle.
• Maintenance drives repeat contact and revenue.
• Replacement needs reinforce retention.

Clinical education events are a key channel for Neuronetics, Inc.: conferences, workshops, and physician training help psychiatrists see NeuroStar data, build trust, and support evidence-based adoption. NeuroStar has been used in over 5 million treatments, so live education can turn clinical proof into faster use.

• Build trust with psychiatrists

• Show real-world outcomes

• Drive evidence-based adoption

Neuronetics, Inc. uses international distribution partners to sell outside the U.S., which helps widen access for its transcranial magnetic stimulation platform without building every local sales team itself. This matters for global growth because the Company reported $65.6 million in 2024 revenue, and partner-led channels can speed entry into new markets.

• Extends reach beyond the U.S.
• Lowers local go-to-market burden.
• Supports international commercial expansion.

Integrated health systems and integrated delivery networks are a strong fit because they can standardize treatment across dozens of sites and buy at scale. For Neuronetics, Inc., these accounts matter because one system win can expand into many placements, while buyers favor evidence-backed care with lower per-site rollout friction.

• Standardize care across multiple sites
• Prioritize scalable, evidence-backed treatment
• Can drive larger multi-site placements

Adult patients with major depressive disorder are the end users of Neuronetics, Inc.’s NeuroStar therapy; the system is positioned for adults diagnosed with MDD, a U.S. condition affecting about 21 million adults, or 8.3%, in 2021. Patient demand drives provider adoption, since more eligible adults seeking non-drug care translates into more clinic referrals and treatment volume.

• End users: adults with MDD
• U.S. MDD: 21 million adults
• Patient need drives provider demand

Neuronetics, Inc. bears steady regulatory and clinical compliance costs to keep FDA clearance and support market access. In FY2025, these outlays sit inside R&D and SG&A, funding evidence generation, post-market monitoring, and quality systems that protect commercialization.

• FDA and quality compliance are ongoing costs
• Clinical evidence supports reimbursement and access
• Noncompliance can block sales

General and administrative overhead at Neuronetics, Inc. covers corporate functions, headquarters work, and support staff, so it stays a fixed cost base that supports the business across finance, legal, HR, and operations. Neuronetics is headquartered in Malvern, Pennsylvania, and this overhead anchors the company’s day-to-day control and compliance work.

• Fixed corporate cost base
• Headquarters in Malvern, Pennsylvania
• Supports company-wide functions

Neuronetics, Inc. earns accessory and replacement-part revenue from its installed NeuroStar systems, since medical devices need ongoing consumables and components over time. This stream tends to track the installed base and can create steadier recurring sales; in FY2025, Neuronetics reported total revenue of $91.6 million, with a meaningful share tied to recurring system use.

• Tracks installed NeuroStar base
• Supports recurring revenue
• Depends on ongoing device use

Training and support fees add a recurring layer to Neuronetics, Inc.’s model: clinics pay for implementation, staff training, and ongoing help so they can use NeuroStar effectively. These services also deepen customer ties, which matters in a market where each treatment course can involve 30+ sessions and steady clinic follow-up.

• Implementation fees support first use.
• Ongoing help drives repeat revenue.
• Training improves clinic adoption.
• Service ties strengthen retention.